贝伐珠单抗联合培美曲塞与顺铂化疗对肺腺癌患者细胞因子及免疫指标的影响观察

Observation of the Impact of Bevacizumab Combined with Pemetrexed and Cisplatin Chemotherapy on Cytokines and Immune Indicators in Lung Adenocarcinoma Patients

目的探究肺腺癌患者的临床治疗期间应用培美曲塞与顺铂化疗联合应用贝伐珠单抗的价值。方法选取漯河市中心医院呼吸与危重症医学科2022年2月至2023年12月期间收治的68例肺腺癌患者,均接受常规化疗(培美曲塞与顺铂),同时依据方案的差异性将其分为对照组(n=34,常规化疗),研究组(n=34,贝伐珠单抗^(+)常规化疗),比较两组疾病控制率、细胞因子、免疫功能及不良反应情况。结果治疗后,研究组疾病控制率高于对照组,差异具有统计学意义(P<0.05);治疗前,两组血管内皮细胞因子水平比较,差异无统计学意义(P>0.05),治疗后,两组血管内皮细胞因子水平均降低,且研究组血管内皮细胞因子水平低于对照组,差异均有统计学意义(P<0.05);治疗前,两组免疫指标情况比较,差异无统计学意义(P>0.05);治疗后,两组CD8^(+)T水平均降低,CD3^(+)T、CD4^(+)T、CD4^(+)T/CD8^(+)T水平均提升,且研究组CD8^(+)T水平低于对照组,CD3^(+)T、CD4^(+)T、CD4^(+)T/CD8^(+)T水平高于对照组,差异均有统计学意义(P<0.05);治疗后,两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论肺腺癌患者临床治疗期间在培美曲塞与顺铂化疗的基础上应用贝伐珠单抗能够提升疗效,改善血管内皮细胞因子及免疫指标,具有一定安全性,值得临床应用。

Objective To explore the value of applying bevacizumab in combination with pemetrexed and cisplatin chemotherapy in the clinical treatment of lung adenocarcinoma patients.Methods A total of 68 lung adenocarcinoma patients treated at the Department of Respiratory and Critical Care Medicine of Luohe Central Hospital from February 2022 to December 2023 were selected.All patients received conventional chemotherapy(pemetrexed and cisplatin).They were divided into two groups based on the treatment plan:the control group(n=34,conventional chemotherapy)and the study group(n=34,bevacizumab^(+)conventional chemotherapy).Disease control rate,cytokines,immune function,and adverse reactions were compared between the two groups.Results After treatment,the disease control rate in the study group was higher than that in the control group,with statistically significant differences(P<0.05).Before treatment,there were no significant differences in vascular endothelial cell cytokine levels between the two groups(P>0.05).After treatment,the vascular endothelial cell cytokine levels in both groups decreased,with the study group showing lower levels than the control group(P<0.05).Before treatment,there were no significant differences in immune indicators between the two groups(P>0.05).After treatment,CD8^(+)T levels decreased,and CD3^(+)T,CD4^(+)T,and CD4^(+)T/CD8^(+)T levels increased in both groups.The study group showed lower CD8^(+)T levels and higher CD3^(+)T,CD4^(+)T,and CD4^(+)T/CD8^(+)T levels compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion The application of bevacizumab in combination with pemetrexed and cisplatin chemotherapy in the clinical treatment of lung adenocarcinoma can improve efficacy,vascular endothelial cell cytokines,and immune indicators,with a certain level of safety,making it worthy of clinical application.